Originally published as JCO Early Release 10.1200/JCO.2005.02.477 on March 7 2005
Journal of Clinical Oncology, Vol 23, No 11 (April 10), 2005: pp. 2544-2555
© 2005 American Society of Clinical Oncology.
Phase I/II Trial Evaluating the Anti-Vascular Endothelial Growth Factor Monoclonal Antibody Bevacizumab in Combination With the HER-1/Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Erlotinib for Patients With Recurrent Non–Small-Cell Lung Cancer
Roy S. Herbst,
David H. Johnson,
Eric Mininberg,
David P. Carbone,
Ted Henderson,
Edward S. Kim,
George Blumenschein, Jr,
Jack J. Lee,
Diane D. Liu,
Mylene T. Truong,
Waun K. Hong,
Hai Tran,
Anne Tsao,
Dong Xie,
David A. Ramies,
Robert Mass,
Somasekar Seshagiri,
David A. Eberhard,
Sean K. Kelley,
Alan Sandler
From the Departments of Thoracic/Head & Neck Medical Oncology, Biostatistics, and Diagnostic Radiology, The University of Texas, M. D. Anderson Cancer Center, Houston, TX; Departments of Medicine and Hematology/Oncology, Vanderbilt University Medical School, The Vanderbilt-Ingram Cancer Center, Nashville, TN; Departments of Pharmacokinetic and Pharmacodynamic Sciences, BioOncology, Microbiology and Pathology, Genentech Inc, South San Francisco, CA
Address reprint requests to Alan Sandler, MD, Vanderbilt-Ingram Cancer Center, 777 Preston Research Building, Nashville, TN 37232-6307; e-mail: alan.sandler{at}vanderbilt.edu.
PURPOSE: Bevacizumab (Avastin; Genentech, South San Francisco, CA) is a recombinant, humanized anti-vascular endothelial growth factor monoclonal antibody. Erlotinib HCl (Tarceva, OSI-774; OSI Pharmaceuticals, New York, NY) is a potent, reversible, highly selective and orally available HER-1/epidermal growth factor receptor tyrosine kinase inhibitor. Preclinical data in various xenograft models produced greater growth inhibition than with either agent alone. Additionally, both agents have demonstrated benefit in patients with previously treated non–small-cell lung cancer (NSCLC).
PATIENTS AND METHODS: A phase I/II study in two centers examined erlotinib and bevacizumab (A+T) in patients with nonsquamous stage IIIB/IV NSCLC with  one prior chemotherapy. In phase I, erlotinib 150 mg/day orally plus bevacizumab 15 mg/kg intravenously every 21 days was established as the phase II dose, although no dose-limiting toxicities were observed. Phase II assessed the efficacy and tolerability of A+T at this dose. Pharmacokinetic parameters were evaluated.
RESULTS: Forty patients were enrolled and treated in this study (34 patients at phase II dose); the median age was 59 years (range, 36 to 72 years), 21 were female, 30 had adenocarcinoma histology, nine were never-smokers, and 22 had two prior regimens (three patients had four prior regimens). The most common adverse events were mild to moderate rash, diarrhea, and proteinuria. Preliminary data showed no pharmacokinetic interaction between A+T. Eight patients (20.0%; 95% CI, 7.6% to 32.4%) had partial responses and 26 (65.0%; 95% CI, 50.2% to 79.8%) had stable disease as their best response. The median overall survival for the 34 patients treated at the phase II dose was 12.6 months, with progression-free survival of 6.2 months.
CONCLUSION: Encouraging antitumor activity and safety of A+T support further development of this combination for patients with advanced NSCLC and other solid tumors.
Supported by Genentech Inc, South San Francisco, CA
Previously presented at the 39th Annual Meeting of the American Society of Clinical Oncology (ASCO), Chicago, IL, May 31-June 3; 40th ASCO Annual Meeting, New Orleans, LA, June 5-8, 2004; and 10th World Congress on Lung Cancer, Vancouver, Canada, August 10-14, 2004.
Terms in blue are defined in the glossary, found at the end of this issue and online at www.jco.org.
Authors' disclosures of potential conflicts of interest are found at the end of this article.
 CiteULike  Complore  Connotea  Del.icio.us  Digg  Facebook  Reddit  Technorati  Twitter What's this?
This article has been cited by other articles:
|
|
|
|
 
M. A. Socinski, C. J. Langer, J. E. Huang, M. M. Kolb, P. Compton, L. Wang, and W. Akerley
Safety of Bevacizumab in Patients With Non-Small-Cell Lung Cancer and Brain Metastases
J. Clin. Oncol.,
November 1, 2009;
27(31):
5255 - 5261.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. Horn and A. Sandler
Epidermal Growth Factor Receptor Inhibitors and Antiangiogenic Agents for the Treatment of Non-Small Cell Lung Cancer
Clin. Cancer Res.,
August 15, 2009;
15(16):
5040 - 5048.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. S. Shord, L. R. Bressler, L. A. Tierney, S. Cuellar, and A. George
Understanding and managing the possible adverse effects associated with bevacizumab
Am. J. Health Syst. Pharm.,
June 1, 2009;
66(11):
999 - 1013.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. Rossi, G. Pelosi, P. Graziano, M. Barbareschi, and M. Papotti
Review Article: A Reevaluation of the Clinical Significance of Histological Subtyping of Non--Small-Cell Lung Carcinoma: Diagnostic Algorithms in the Era of Personalized Treatments
International Journal of Surgical Pathology,
June 1, 2009;
17(3):
206 - 218.
[Abstract]
[PDF]
|
|
|
|
|
|
|
J. R. TONRA, E. CORCORAN, D. S. DEEVI, P. STEINER, J. KEARNEY, H. LI, D. L. LUDWIG, Z. ZHU, L. WITTE, D. SURGULADZE, et al.
Prioritization of EGFR/IGF-IR/VEGFR2 Combination Targeted Therapies Utilizing Cancer Models
Anticancer Res,
June 1, 2009;
29(6):
1999 - 2007.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Dubey and C. A. Powell
Update in Lung Cancer 2008
Am. J. Respir. Crit. Care Med.,
May 15, 2009;
179(10):
860 - 868.
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. Schicher, V. Paulitschke, A. Swoboda, R. Kunstfeld, R. Loewe, P. Pilarski, H. Pehamberger, and C. Hoeller
Erlotinib and Bevacizumab Have Synergistic Activity against Melanoma
Clin. Cancer Res.,
May 15, 2009;
15(10):
3495 - 3502.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. Horn and A. B. Sandler
Angiogenesis in the Treatment of Non-Small Cell Lung Cancer
Proceedings of the ATS,
April 15, 2009;
6(2):
206 - 217.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. Sano, S. Choi, Z. L. Milas, G. Zhou, C. E. Galer, Y.-W. Su, M. Gule, M. Zhao, Z. Zhu, and J. N. Myers
The Effect of Combination Anti-Endothelial Growth Factor Receptor and Anti-Vascular Endothelial Growth Factor Receptor 2 Targeted Therapy on Lymph Node Metastasis: A Study in an Orthotopic Nude Mouse Model of Squamous Cell Carcinoma of the Oral Tongue
Arch Otolaryngol Head Neck Surg,
April 1, 2009;
135(4):
411 - 420.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. A. Pennell and T. J. Lynch Jr.
Combined Inhibition of the VEGFR and EGFR Signaling Pathways in the Treatment of NSCLC
Oncologist,
April 1, 2009;
14(4):
399 - 411.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. R. Hecht, E. Mitchell, T. Chidiac, C. Scroggin, C. Hagenstad, D. Spigel, J. Marshall, A. Cohn, D. McCollum, P. Stella, et al.
A Randomized Phase IIIB Trial of Chemotherapy, Bevacizumab, and Panitumumab Compared With Chemotherapy and Bevacizumab Alone for Metastatic Colorectal Cancer
J. Clin. Oncol.,
February 10, 2009;
27(5):
672 - 680.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. N. Dickler, H. S. Rugo, C. A. Eberle, E. Brogi, J. F. Caravelli, K. S. Panageas, J. Boyd, B. Yeh, D. E. Lake, C. T. Dang, et al.
A Phase II Trial of Erlotinib in Combination with Bevacizumab in Patients with Metastatic Breast Cancer
Clin. Cancer Res.,
December 1, 2008;
14(23):
7878 - 7883.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. S. Herbst and A. Sandler
Bevacizumab and Erlotinib: A Promising New Approach to the Treatment of Advanced NSCLC
Oncologist,
November 1, 2008;
13(11):
1166 - 1176.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. P. Carden, J. M.G. Larkin, and M. A. Rosenthal
What is the risk of intracranial bleeding during anti-VEGF therapy?
Neuro-oncol,
August 1, 2008;
10(4):
624 - 630.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Y. Oh, R. S. Herbst, H. Burris, A. Cleverly, L. Musib, M. Lahn, and G. Bepler
Enzastaurin, an Oral Serine/Threonine Kinase Inhibitor, As Second- or Third-Line Therapy of Non-Small-Cell Lung Cancer
J. Clin. Oncol.,
March 1, 2008;
26(7):
1135 - 1141.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. A. Garcia
Small Molecules: Big Changes in the Cancer Treatment Paradigm
Journal of Pharmacy Practice,
February 1, 2008;
21(1):
17 - 35.
[Abstract]
[PDF]
|
|
|
|
|
|
|
E. Van Cutsem, C. Verslype, P. Beale, S. Clarke, R. Bugat, A. Rakhit, S. H. Fettner, U. Brennscheidt, A. Feyereislova, and J.-P Delord
A phase Ib dose-escalation study of erlotinib, capecitabine and oxaliplatin in metastatic colorectal cancer patients
Ann. Onc.,
February 1, 2008;
19(2):
332 - 339.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. L. G. Bender, P. C. Adamson, J. M. Reid, L. Xu, S. Baruchel, Y. Shaked, R. S. Kerbel, E. M. Cooney-Qualter, D. Stempak, H. X. Chen, et al.
Phase I Trial and Pharmacokinetic Study of Bevacizumab in Pediatric Patients With Refractory Solid Tumors: A Children's Oncology Group Study
J. Clin. Oncol.,
January 20, 2008;
26(3):
399 - 405.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. S. Ramalingam, S. E. Dahlberg, C. J. Langer, R. Gray, C. P. Belani, J. R. Brahmer, A. B. Sandler, J. H. Schiller, and D. H. Johnson
Outcomes for Elderly, Advanced-Stage Non Small-Cell Lung Cancer Patients Treated With Bevacizumab in Combination With Carboplatin and Paclitaxel: Analysis of Eastern Cooperative Oncology Group Trial 4599
J. Clin. Oncol.,
January 1, 2008;
26(1):
60 - 65.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. S. Herbst, V. J. O'Neill, L. Fehrenbacher, C. P. Belani, P. D. Bonomi, L. Hart, O. Melnyk, D. Ramies, M. Lin, and A. Sandler
Phase II Study of Efficacy and Safety of Bevacizumab in Combination With Chemotherapy or Erlotinib Compared With Chemotherapy Alone for Treatment of Recurrent or Refractory Non Small-Cell Lung Cancer
J. Clin. Oncol.,
October 20, 2007;
25(30):
4743 - 4750.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Gridelli, P. Maione, A. Rossi, and F. De Marinis
The Role of Bevacizumab in the Treatment of Non-Small Cell Lung Cancer: Current Indications and Future Developments
Oncologist,
October 1, 2007;
12(10):
1183 - 1193.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. V. Heymach, B. E. Johnson, D. Prager, E. Csada, J. Roubec, M. Pesek, I. Spasova, C. P. Belani, I. Bodrogi, S. Gadgeel, et al.
Randomized, Placebo-Controlled Phase II Study of Vandetanib Plus Docetaxel in Previously Treated Non Small-Cell Lung Cancer
J. Clin. Oncol.,
September 20, 2007;
25(27):
4270 - 4277.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. Seitz and H. Zhou
Pharmacokinetic Drug-Drug Interaction Potentials for Therapeutic Monoclonal Antibodies: Reality Check
J. Clin. Pharmacol.,
September 1, 2007;
47(9):
1104 - 1118.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
I. Duran, S. J. Hotte, H. Hirte, E. X. Chen, M. MacLean, S. Turner, L. Duan, G. R. Pond, C. Lathia, S. Walsh, et al.
Phase I Targeted Combination Trial of Sorafenib and Erlotinib in Patients with Advanced Solid Tumors
Clin. Cancer Res.,
August 15, 2007;
13(16):
4849 - 4857.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Perez-Soler
Erlotinib: Recent Clinical Results and Ongoing Studies in Non Small Cell Lung Cancer
Clin. Cancer Res.,
August 1, 2007;
13(15):
4589s - 4592s.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. Morgensztern and R. Govindan
Is There a Role for Cetuximab in Non Small Cell Lung Cancer?
Clin. Cancer Res.,
August 1, 2007;
13(15):
4602s - 4605s.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Sandler
Bevacizumab in Non Small Cell Lung Cancer
Clin. Cancer Res.,
August 1, 2007;
13(15):
4613s - 4616s.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. O. Hanrahan and J. V. Heymach
Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitors Vandetanib (ZD6474) and AZD2171 in Lung Cancer
Clin. Cancer Res.,
August 1, 2007;
13(15):
4617s - 4622s.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Gridelli, M. A. Bareschino, C. Schettino, A. Rossi, P. Maione, and F. Ciardiello
Erlotinib in Non-Small Cell Lung Cancer Treatment: Current Status and Future Development
Oncologist,
July 1, 2007;
12(7):
840 - 849.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. D. Hainsworth, D. R. Spigel, C. Farley, D. S. Thompson, D. L. Shipley, and F. A. Greco
Phase II Trial of Bevacizumab and Erlotinib in Carcinomas of Unknown Primary Site: The Minnie Pearl Cancer Research Network
J. Clin. Oncol.,
May 1, 2007;
25(13):
1747 - 1752.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. Giaccone
The Potential of Antiangiogenic Therapy in Non-Small Cell Lung Cancer
Clin. Cancer Res.,
April 1, 2007;
13(7):
1961 - 1970.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Tabernero
The Role of VEGF and EGFR Inhibition: Implications for Combining Anti-VEGF and Anti-EGFR Agents
Mol. Cancer Res.,
March 1, 2007;
5(3):
203 - 220.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. V. Sequist
Second-Generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer
Oncologist,
March 1, 2007;
12(3):
325 - 330.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
W. Wu, A. Onn, T. Isobe, S. Itasaka, R. R. Langley, T. Shitani, K. Shibuya, R. Komaki, A. J. Ryan, I. J. Fidler, et al.
Targeted therapy of orthotopic human lung cancer by combined vascular endothelial growth factor and epidermal growth factor receptor signaling blockade
Mol. Cancer Ther.,
February 1, 2007;
6(2):
471 - 483.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Gridelli, P. Maione, F. Del Gaizo, G. Colantuoni, C. Guerriero, C. Ferrara, D. Nicolella, D. Comunale, A. De Vita, and A. Rossi
Sorafenib and Sunitinib in the Treatment of Advanced Non-Small Cell Lung Cancer
Oncologist,
February 1, 2007;
12(2):
191 - 200.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A.-R. Hanauske, J. Cassidy, J. Sastre, C. Bolling, R. J. Jones, A. Rakhit, S. Fettner, U. Brennscheidt, A. Feyereislova, and E. Diaz-Rubio
Phase 1b Dose Escalation Study of Erlotinib in Combination with Infusional 5-Fluorouracil, Leucovorin, and Oxaliplatin in Patients with Advanced Solid Tumors
Clin. Cancer Res.,
January 15, 2007;
13(2):
523 - 531.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. Giaccone, M. Gallegos Ruiz, T. Le Chevalier, N. Thatcher, E. Smit, J. A. Rodriguez, P. Janne, D. Oulid-Aissa, and J.-C. Soria
Erlotinib for Frontline Treatment of Advanced Non-Small Cell Lung Cancer: a Phase II Study.
Clin. Cancer Res.,
October 15, 2006;
12(20):
6049 - 6055.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Sandler and R. Herbst
Combining targeted agents: blocking the epidermal growth factor and vascular endothelial growth factor pathways.
Clin. Cancer Res.,
July 15, 2006;
12(14):
4421s - 4425s.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. A. Adjei
Novel combinations based on epidermal growth factor receptor inhibition.
Clin. Cancer Res.,
July 15, 2006;
12(14):
4446s - 4450s.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. A. Sosman and I. Puzanov
Molecular targets in melanoma from angiogenesis to apoptosis.
Clin. Cancer Res.,
April 1, 2006;
12(7):
2376s - 2383s.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. S. Ettinger
Clinical Implications of EGFR Expression in the Development and Progression of Solid Tumors: Focus on Non-Small Cell Lung Cancer.
Oncologist,
April 1, 2006;
11(4):
358 - 373.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Ling, K. A. Johnson, Z. Miao, A. Rakhit, M. P. Pantze, M. Hamilton, B. L. Lum, and C. Prakash
METABOLISM AND EXCRETION OF ERLOTINIB, A SMALL MOLECULE INHIBITOR OF EPIDERMAL GROWTH FACTOR RECEPTOR TYROSINE KINASE, IN HEALTHY MALE VOLUNTEERS
Drug Metab. Dispos.,
March 1, 2006;
34(3):
420 - 426.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Frohna, J. Lu, S. Eppler, M. Hamilton, J. Wolf, A. Rakhit, J. Ling, S. R. Kenkare-Mitra, and B. L. Lum
Evaluation of the absolute oral bioavailability and bioequivalence of erlotinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in a randomized, crossover study in healthy subjects.
J. Clin. Pharmacol.,
March 1, 2006;
46(3):
282 - 290.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Maione, C. Gridelli, T. Troiani, and F. Ciardiello
Combining Targeted Therapies and Drugs with Multiple Targets in the Treatment of NSCLC.
Oncologist,
March 1, 2006;
11(3):
274 - 284.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Sahni, A. A. Khorana, R. B. Baggs, H. Peng, and C. W. Francis
FGF-2 binding to fibrin(ogen) is required for augmented angiogenesis
Blood,
January 1, 2006;
107(1):
126 - 131.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. S. Jassar, E. Suzuki, V. Kapoor, J. Sun, M. B. Silverberg, L. Cheung, M. D. Burdick, R. M. Strieter, L.-M. Ching, L. R. Kaiser, et al.
Activation of Tumor-Associated Macrophages by the Vascular Disrupting Agent 5,6-Dimethylxanthenone-4-Acetic Acid Induces an Effective CD8+ T-Cell-Mediated Antitumor Immune Response in Murine Models of Lung Cancer and Mesothelioma
Cancer Res.,
December 15, 2005;
65(24):
11752 - 11761.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. D. Hainsworth, J. A. Sosman, D. R. Spigel, D. L. Edwards, C. Baughman, and A. Greco
Treatment of Metastatic Renal Cell Carcinoma With a Combination of Bevacizumab and Erlotinib
J. Clin. Oncol.,
November 1, 2005;
23(31):
7889 - 7896.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. G. McNeel, J. Eickhoff, F. T. Lee, D. M. King, D. Alberti, J. P. Thomas, A. Friedl, J. Kolesar, R. Marnocha, J. Volkman, et al.
Phase I Trial of a Monoclonal Antibody Specific for {alpha}v{beta}3 Integrin (MEDI-522) in Patients with Advanced Malignancies, Including an Assessment of Effect on Tumor Perfusion
Clin. Cancer Res.,
November 1, 2005;
11(21):
7851 - 7860.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. S. Herbst, A. Onn, and A. Sandler
Angiogenesis and Lung Cancer: Prognostic and Therapeutic Implications
J. Clin. Oncol.,
May 10, 2005;
23(14):
3243 - 3256.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Baselga and C. L. Arteaga
Critical Update and Emerging Trends in Epidermal Growth Factor Receptor Targeting in Cancer
J. Clin. Oncol.,
April 10, 2005;
23(11):
2445 - 2459.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
